Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is a provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey, from diagnosis to treatment selection and monitoring. The company is based in Redwood City, California, with European headquarters in Geneva, Switzerland.

TORONTO--(BUSINESS WIRE)-- #Genechat--London North West University Healthcare NHS Trust unites multiple geographically distinct hospitals with PhenoTips' cloud-hosted Genomic Health Record.

London North West University Healthcare NHS Trust Finds Digital Way Forward with PhenoTips' Genomic Health Record

TORONTO--(BUSINESS WIRE)-- #GMS--The NHS East Genomic Medicine Service Alliance Harnesses PhenoTips' Genomic Health Record in a Milestone Regional Transformation Project.

The NHS East Genomic Medicine Service Alliance Harnesses PhenoTips' Genomic Health Record in a Milestone Regional Transformation Project

Genomic Health (GHDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why the Earnings Surprise Streak Could Continue for Genomic Health (GHDX)

Genomic Health (GHDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Genomic Health (GHDX) Earnings Expected to Grow: Should You Buy?

NeoGenomics

Invitae

Most stocks in the industry cooled off from all-time highs. Will they keep sliding?

Here's Why Genetic Testing Stocks Tumbled in September

Genomic Health (GHDX) is on course to realize its impending merger with cancer diagnostics major Exact Sciences, which will integrate brands like Cologuard and OncotypeDX.

Innovation Aids Genomic Health, Merger Procedure on Track

Genomic Health (GHDX) reported earnings 30 days ago. What's next for the stock?

Why Is Genomic Health (GHDX) Down 0.5% Since Last Earnings Report?

This is a major development in Genomic Health's (GHDX) endeavor to strengthen its breast cancer treatment portfolio.

Genomic Health Test to Guide Chemo Per New Breast Cancer Rule

President and CEO of Genomic Health Inc (30-Year Financial, Insider Trades) Kimberly J Popovits (insider trades) sold 50,000 shares of GHDX on 08/13/2019 at an average price of $73.76 a share.

Genomic Health Inc (GHDX) President and CEO Kimberly J Popovits Sold $3.7 million of Shares

Exact Sciences takes out the cancer-test maker for $2.8 billion.

Genomic Health's Second Quarter Was So Great It Got the Company Acquired

Exact Sciences

It was a great month to be a genetic testing company.

Here's Why Genetic Testing Stocks Rose as Much as 25.4% in July

As of late, it has definitely been a great time to be an investor in Genomic Health, Inc. (GHDX).

Genomic Health, Inc. (GHDX) Shares March Higher, Can It Continue?

The merger of Genomic Health (GHDX) with Exact Sciences will combine two of the strongest brands in cancer diagnostics, Cologuard and OncotypeDX, providing platform for growth.

Genomic Health (GHDX) to Join Exact Sciences, Posts Q2 Results

Shares of the two cancer diagnostic companies are heading in opposite directions after they surprised Wall Street by revealing plans to merge. Here's what investors need to know.

Why Exact Sciences Is Sinking and Genomic Health Is Rising

Exact Sciences Corp  said on Monday it will buy peer Genomic Health Inc  for about $2.8 billion in cash and stock, expanding the cancer diagnostic company's testing capabilities to breast and prostate cancers.

Diagnostic company Exact Sciences to buy Genomic Health in $2.8 billion deal

Genomic Health (GHDX) delivered earnings and revenue surprises of 20.00% and 2.91%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Genomic Health (GHDX) Surpasses Q2 Earnings and Revenue Estimates

Exact Sciences Corp. (NASDAQ: EXAS) will acquire Genomic Health, Inc. (NASDAQ: GHDX) for $72 per share in a cash and stock transaction valued at $2.8 billion.

Exact Sciences Will Acquire Genomic Health In $2.8B Deal

Cancer diagnostics company Exact Sciences Corp  said on Monday it will buy healthcare company Genomic Health Inc  for about $2.8 billion to bolster its cancer testing business.

Exact Sciences to buy Genomic Health for $2.8 billion

Molecular diagnostics company Exact Sciences Corp. EXAS, +1.64% and Genomic Health Inc. which makes genomic-based diagnostic tests, said Monday they have agreed to combine in a deal valued at $2.8 billion.

Exact Sciences to combine with Genomic Health in cash and stock deal valued at $2.8 billion

Cancer diagnostics company Exact Sciences Corp  is in advanced negotiations to buy healthcare company Genomic Health Inc  for about $2.8 billion to strengthen its cancer testing, Bloomberg reported on Saturday.

Exact Sciences in advanced talks to buy Genomic Health for $2.8 billion: Bloomberg

Genomic Health (GHDX) to Report Q2 Results: Wall Street Expects Earnings Growth

It had nothing to do with the underlying value of the company.

Here's Why Genomic Health Jumped Almost 15% Today

Brookfield Infrastructure Partners L.P.

Invest for the long term with these three stocks.

Three Stocks to Buy Ahead of the Next Market Crash

Why Is Genomic Health (GHDX) Down 5% Since Last Earnings Report?

Myriad Genetics

Wall Street soured on the high-growth industry after first-quarter earnings were reported, but it may have been an overreaction for two stocks.

News for Genomic Health Stock (GHDX)